CEimpact Podcast

STIs Part III: Gonorrhea and Chlamydia

June 06, 2022 CEimpact Season 3 Episode 23
CEimpact Podcast
STIs Part III: Gonorrhea and Chlamydia
Show Notes

The Centers for Disease Control and Prevention just updated guidelines for sexually transmitted infections (previously sexually transmitted diseases) for everything by HIV. In this multi-part series, host Geoff Wall will break down what’s new and what’s changing in practice.

The GameChanger
A 7-day course of doxycycline in the treatment of urogenital chlamydia is preferred and has been shown to be more efficacious compared to azithromycin. Ceftriaxone should be the treatment of choice for gonorrhea as there have been no “resistance”-related treatment failures identified in the United States at any anatomical site. 

 Show Segments
00:00 – Introduction
01:45 – STI Guidelines
02:34 – Chlamydia 
14:56 – Gonorrhea 
28:57 – Closing Remarks

Host
Geoff Wall, PharmD., BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University 
Internal Medicine/Critical Care, UnityPoint Health 

All relevant financial relationships have been mitigated. 

References and Resources
CDC Sexually Transmitted Infections Treatment Guidelines, 2021

Redeem your CPE or CME

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

 CE Information 

Learning Objectives 

  1. Describe the treatment of Neisseria gonorrhea based on the 2021 recommendations
  2. Discuss pharmacotherapy options for patients with chlamydia with or without concomitant gonorrhea infections

0.05 CEU/0.5 Hr
UAN: 0107-0000-22-224-H01-P
Initial release date: 06/062022
Expiration date: 06/06/2023
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram